Cont…. MusS is a strong modifiable risk factor for several CVDs, but also CVD-related mortality and all-cause mortality. Except for the risk of HTN, where the evidence is conflicting, MusS seems to exert protective effects on several CV and metabolic conditions ( ie , MetS , T2DM, and obesity). Importantly, such effects seem to be, for the most part, independent of the amount of LM, CRF, and physical activity. The studies discussed herein, however, cannot prove whether dynapenia is a mediator or perhaps only a marker of overall worse nutritional status able to identify those with frailty and sarcopenia among others, which, in turn, confer a greater risk for cardiometabolic diseases. In other words, is this relationship causal or merely association? Further study is clearly warranted to determine whether therapeutics, including targeting nutrition and RT, aimed at increasing MusS , with and without changes in LM, can, in fact, affect major clinical outcomes, and whether this can be implemented to improve cardiac rehabilitation outcomes in patients with established CVD, especially CHD and HF.